Protalix BioTherapeutics, Inc. $PLX Shares Purchased by Goldman Sachs Group Inc.

Key Points

• Goldman Sachs Group Inc. increased its stake in Protalix BioTherapeutics by 482.3%, acquiring an additional 239,751 shares, bringing its total holdings to 289,461 shares worth approximately $741,000.
• Protalix BioTherapeutics shares have experienced a decline of 3.9%, opening at $1.96 with a market cap of $156.27 million.
• Institutional ownership in Protalix stands at 16.53%, with several firms like NewEdge Advisors LLC and Jane Street Group LLC significantly increasing their stakes recently.

Goldman Sachs Group Inc. grew its holdings in Protalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) by 482.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 289,461 shares of the company's stock after acquiring an additional 239,751 shares during the period. Goldman Sachs Group Inc. owned about 0.36% of Protalix BioTherapeutics worth $741,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in PLX. NewEdge Advisors LLC acquired a new stake in Protalix BioTherapeutics in the 1st quarter valued at $39,000. XTX Topco Ltd acquired a new stake in shares of Protalix BioTherapeutics in the first quarter valued at about $107,000. Cubist Systematic Strategies LLC raised its holdings in shares of Protalix BioTherapeutics by 82.1% during the 1st quarter. Cubist Systematic Strategies LLC now owns 53,380 shares of the company's stock valued at $137,000 after buying an additional 24,073 shares during the period. Squarepoint Ops LLC lifted its position in shares of Protalix BioTherapeutics by 33.4% during the fourth quarter. Squarepoint Ops LLC now owns 73,940 shares of the company's stock worth $139,000 after purchasing an additional 18,522 shares in the last quarter. Finally, Jane Street Group LLC lifted its holdings in Protalix BioTherapeutics by 147.2% in the 4th quarter. Jane Street Group LLC now owns 113,616 shares of the company's stock worth $214,000 after buying an additional 67,664 shares in the last quarter. 16.53% of the stock is owned by hedge funds and other institutional investors.

Protalix BioTherapeutics Stock Down 3.9%

Shares of NYSE PLX opened at $1.96 on Wednesday. Protalix BioTherapeutics, Inc. has a fifty-two week low of $0.99 and a fifty-two week high of $3.10. The firm has a market cap of $156.27 million, a PE ratio of -15.08 and a beta of -0.23. The business has a 50 day moving average price of $1.61 and a two-hundred day moving average price of $1.89.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.

Want to see what other hedge funds are holding PLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protalix BioTherapeutics, Inc. (NYSE:PLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.